The Cooper Companies, Inc.’s (COO) first-quarter fiscal 2024 results are scheduled to be released on Feb 29, after the closing bell.In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate. Its earnings beat estimates in two of the trailing four quarters and met twice, delivering an average surprise of 2.84%.Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $915.2 million for the soon-to-be-reported quarter, indicating a 6.6% increase from the year ...

Wall Street expects a year-over-year increase in earnings on higher revenues when The Cooper Companies (COO) reports results for the quarter ended January 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Feb ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or The Cooper Companies (COO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with st ...

SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol "COO". The stock split supports Cooper's desire to make ownership of its stock more accessible to employees and investors. Cooper previously announced on its fourth qua ...

The Cooper Companies’ (COO) wholly-owned subsidiary CooperSurgical and Fulgent Genetics recently announced their partnership to provide exclusive newborn genetic screening panels to Cord Blood Registry (CBR) families.As a result of this collaboration, CBR by CooperSurgical brand will offer families a variety of genetic testing choices by utilizing Fulgent's Picture Genetics platform.Price PerformanceFor the past six months, COO’s shares have lost 0.3% compared with the industry’s decline of 2.3%. The S&P 50 ...

The Cooper Companies, Inc. (COO) is well-poised for growth, backed by strong prospects in its CooperVision (CVI) and CooperSurgical (CSI) business segments. Acquisitions boost the company’s portfolio and buoy optimism. However, unfavorable currency movements and rising costs continue to hurt revenues and margins, respectively.Shares of this currently Zacks Rank #3 (Hold) company have risen 11.3% in the past year compared with the industry's 10.8% growth. The S&P 500 Index has gained 22.1% in the same time f ...

SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2024 financial results on Thursday, February 29, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 5337119. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.c ...

Financial Data and Key Metrics Changes - The company reported record revenues of almost $3.6 billion for the fiscal year 2023, representing a 9% increase year-over-year, or 10% on an organic basis [14][47] - For Q4 2023, consolidated revenues were $927 million, up 9% organically year-over-year [15][44] - Non-GAAP earnings per share (EPS) for Q4 was $3.47, up 26% year-over-year [22][46] - Consolidated gross margin improved to 66.7%, up from 65% last year, driven by better operational performance [44] Business Line Data and Key Metrics Changes - CooperVision revenues were $623 million, up 11% organically, while CooperSurgical revenues were $304 million, up 7% organically [15][34] - The daily silicone hydrogel portfolio, particularly MyDay, showed strong growth, with Daily Silicone Hydrogel lenses growing 19% [23][26] - Myopia management revenues reached $35 million, up 41%, with MiSight growing 46% [29] Market Data and Key Metrics Changes - CooperVision's growth was led by the Americas, which grew 12%, EMEA grew 9%, and Asia Pacific grew 10% [22] - The contact lens market grew approximately 7% in calendar Q3, with CooperVision taking market share and growing 10% [31] - The company expects the contact lens market to remain healthy, growing 5% to 7% in the coming year [31] Company Strategy and Development Direction - The company aims to gain market share, drive profitability, and launch innovative products while maintaining its culture [21] - There is a focus on expanding the MyDay product line and addressing capacity constraints to meet demand [40][41] - The company is also investing in geographic expansion and R&D within CooperSurgical, particularly in the fertility market [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth despite capacity challenges, particularly for MyDay products [40][56] - The company anticipates a solid Q1 2024, with guidance for CooperVision's organic revenue growth set at 7% to 9% for the year [40][50] - Management highlighted the ongoing demand for contact lenses and the expected long-term growth in the industry due to increasing myopia rates [32][36] Other Important Information - The company announced a four-for-one stock split effective February 16, 2024, to make ownership more accessible [52] - The acquisition of select Cook Medical assets for $300 million is expected to be accretive to non-GAAP earnings per share by approximately $0.20 in fiscal 2024 [49] Q&A Session Summary Question: What is the outlook for CooperVision's revenue growth and pricing strategy? - Management indicated that they expect to achieve around 7% growth in Q1, with capacity constraints impacting potential growth [56][57] - They confirmed that pricing will be at the higher end of market expectations, which is around 2% to 3% [57] Question: How will operating margin expansion be achieved? - Management noted that operating income grew 11% on a constant currency basis and emphasized their focus on improving operating margins [64] Question: Are there any concerns about losing customers due to capacity challenges? - Management reassured that they are not losing customers and continue to gain new wearers, although capacity constraints may limit growth [89] Question: What is the company's strategy regarding foreign exchange impacts? - Management stated that if the dollar weakens, they plan to let the benefits flow through to the bottom line [91] Question: What is the status of the MiSight product and its insurance coverage? - Management indicated that they are in the early stages of insurance coverage for MiSight, with reimbursement rates varying significantly [113][115]

CooperCompanies Fiscal 2024 financial guidance FY24 Guidance* Sales Note: Sales $ in millions; Organic growth excludes the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures, or discontinuations that occurred in the comparable period. Non-GAAP and organic – a reconciliation of these measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section in our earning releases and under the "Management's Discussion and Analysis of Financia ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED OCTOBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO (925) 460-3600 (Registrant's telephone number, including area code) ________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $.10 par valu ...